Keyword: Turnstone Biologics
Pfizer creates COO role, Bayer replaces consumer health chief, Turnstone poaches Bristol-Myers executive as new R&D head and more.
Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.
The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
Turnstone Biologics will use its new cash pot to both boost and expand its pipeline of oncolytic viral immunotherapies with help from new investors OrbiMed and F-Prime Capital Partners.